Developing new indications
for approved medicines in hematologic malignancies
using a proprietary continuous delivery platform.

Targeted continuous delivery

We reimagine FDA-approved medicines and leverage our delivery system to establish new profiles. Our platform technology allows for lower drug exposure and the potential for improved efficacy.

Careers

Building a team dedicated to delivering breakthrough, transformative products for patients with blood cancers. We offer comprehensive and competitive health, financial, paid time off and many other benefits designed to promote the health and well-being of our employees and their families.

News and Events

April 7, 2021

Starton Therapeutics to Participate in the Virtual 20th Annual Needham Healthcare Conference

PARAMUS, N.J., APRIL 7, 2021 – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology company with a continuous delivery platform of approved drugs in novel indications,…

March 22, 2021

Starton Therapeutics Completes Pre-IND Meeting with FDA: Clearing Path to Phase 1 Clinical Study for STAR-LLD Continuous Infusion

PARAMUS, N.J., MARCH 22, 2021 – Starton Therapeutics Inc. (“Starton” or the “Company”), a clinical stage biotechnology company with a continuous delivery platform of approved drugs in novel indications,…